Kymera Therapeutics Advances KT-485 in Sanofi Collaboration

Kymera Therapeutics ( (KYMR) ) has shared an announcement.

On June 25, 2025, Kymera Therapeutics announced an update on its collaboration with Sanofi, highlighting the advancement of KT-485, an oral IRAK4 degrader, into clinical studies for immuno-inflammatory diseases. This decision, which includes a $20 million milestone achievement for Kymera, marks a strategic shift from KT-474 to KT-485, reflecting its superior preclinical profile and potential to transform immunology treatments. The collaboration could yield up to $975 million in clinical, regulatory, and commercial milestones, positioning Kymera strongly in the biopharmaceutical industry.

The most recent analyst rating on (KYMR) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.

Spark’s Take on KYMR Stock

According to Spark, TipRanks’ AI Analyst, KYMR is a Neutral.

Kymera Therapeutics’ overall stock score reflects a mix of strong technical indicators and promising corporate developments, tempered by financial challenges. The company’s robust pipeline and strategic focus on high-value programs enhance its future potential, despite current profitability issues.

To see Spark’s full report on KYMR stock, click here.

More about Kymera Therapeutics

Kymera Therapeutics is a clinical-stage biotechnology company specializing in targeted protein degradation to develop innovative oral small molecule degrader medicines for immunological diseases. Founded in 2016, the company aims to transform treatment paradigms by addressing disease targets and pathways that are inaccessible with conventional therapeutics.

Average Trading Volume: 878,798

Technical Sentiment Signal: Strong Buy

Current Market Cap: $3.01B

See more data about KYMR stock on TipRanks’ Stock Analysis page.